HEALTHKSTP ABC MINNEAPOLIS
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.
Mentioned
Related Signal
Adjacent reporting
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
- STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
- FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures
- FDA to weigh lifting restrictions on some MAHA-favored peptides